توقعات سوق الصرع في منطقة آسيا والمحيط الهادئ حتى عام 2030 - التحليل الإقليمي - حسب النوع (الصرع الرمعي التدريجي، والصرع الانعكاسي، والصرع العام، وغيرها)، وطريق الإعطاء (عن طريق الفم، والحقن، وغيرها)، ونوع العلاج (أدوية الجيل الأول، وأدوية الجيل الثاني، وأدوية الجيل الثالث)، والفئة العمرية (البالغين والأطفال)، وقناة التوزيع (صيدليات المستشفيات، وصيدليات التجزئة، وغيرها)

BMIRE00030724 | Pages: 146 | Pharmaceuticals | Sep 2024 | Type: Regional | Status: Published
تم تقييم سوق الصرع في منطقة آسيا والمحيط الهادئ بمبلغ 2200.92 مليون دولار أمريكي في عام 2022 ومن المتوقع أن يصل إلى 3143.44 مليون دولار أمريكي بحلول عام 2030؛ ومن المتوقع أن يسجل معدل نمو سنوي مركب بنسبة 4.6٪ من عام 2022 إلى عام 2030.

زيادة في برنامج التوعية الذي تنفذه المنظمات يعزز سوق الصرع في منطقة آسيا والمحيط الهادئ

أدى الوعي المتزايد بالصرع وأعراضه وأهمية التشخيص المبكر إلى زيادة في عدد المرضى الذين يسعون للحصول على رعاية طبية. تلعب منظمات مثل مؤسسة الصرع وجمعية الصرع والجمعية الأمريكية للصرع وجمعية الصرع في وسط فلوريدا دورًا حاسمًا في تثقيف الناس حول هذا المرض. أدى إشراك هذه المنظمات إلى زيادة معدلات التشخيص وزيادة عدد المرضى الذين يحتاجون إلى علاج الصرع. يتم إجراء العديد من حملات التوعية من قبل المنظمات في جميع أنحاء العالم لنشر الوعي بشأن الحالة والعلاج المتاح. في عام 2023، في اليوم الأرجواني للصرع، عقدت مستشفيات أستر برايم في حيدر أباد (الهند)، بالتعاون مع جمعية المشاة في كريشنا كانت بارك، نشاطًا توعويًا. حضر هذه الجلسة مائة وخمسون مشاركًا في المجموع، بما في ذلك المشاة وممارسي اليوجا. بالإضافة إلى ذلك، من أجل تحسين نوعية حياة الأستراليين الذين يعيشون مع الصرع، تقدم Epilepsy Action Australia مجموعة متنوعة من الأدوات والخدمات التي تهدف إلى زيادة الوعي وتثقيف وتجهيز الأفراد بالمهارات اللازمة. وبالتالي، تؤدي مثل هذه المبادرات وحملات التوعية إلى زيادة تشخيصات وعلاجات الصرع، مما يوفر فرص نمو مربحة للسوق.

نظرة عامة على سوق الصرع في منطقة آسيا والمحيط الهادئ

يتم تحليل سوق الصرع في منطقة آسيا والمحيط الهادئ بناءً على الصين واليابان والهند وأستراليا وكوريا الجنوبية وبقية منطقة آسيا والمحيط الهادئ. وفقًا لتقرير منظمة الصحة العالمية، فإن الصرع أكثر شيوعًا في البلدان النامية منه في البلدان المتقدمة، حيث يمثل انتشارًا بنسبة 6.1٪ و 5.0٪ على التوالي.

إيرادات سوق الصرع في منطقة آسيا والمحيط الهادئ وتوقعاتها حتى عام 2030 (مليون دولار أمريكي)

تجزئة سوق الصرع في منطقة آسيا والمحيط الهادئ

يتم تصنيف سوق الصرع في منطقة آسيا والمحيط الهادئ إلى نوع وطريقة الإدارة ونوع العلاج والفئة العمرية وقناة التوزيع والبلد.

بناءً على النوع، يتم تصنيف سوق الصرع في منطقة آسيا والمحيط الهادئ إلى الصرع الرمعي التدريجي والصرع الانعكاسي والصرع المعمم وغيرها. احتل قطاع الصرع المعمم أكبر حصة سوقية في عام 2022.

من حيث طريقة الإدارة، يتم تصنيف سوق الصرع في منطقة آسيا والمحيط الهادئ إلى عن طريق الفم والحقن وغيرها. احتل القطاع الفموي أكبر حصة سوقية في عام 2022.

حسب نوع العلاج، يتم تقسيم سوق الصرع في منطقة آسيا والمحيط الهادئ إلى أدوية الجيل الأول وأدوية الجيل الثاني وأدوية الجيل الثالث. احتل قطاع أدوية الجيل الثالث أكبر حصة سوقية في عام 2022.

بناءً على الفئة العمرية، ينقسم سوق الصرع في منطقة آسيا والمحيط الهادئ إلى البالغين والأطفال. احتل قطاع البالغين حصة سوقية أكبر في عام 2022.

من حيث قناة التوزيع، يتم تصنيف سوق الصرع في منطقة آسيا والمحيط الهادئ إلى صيدليات المستشفيات وصيدليات التجزئة وغيرها. احتل قطاع صيدليات المستشفيات أكبر حصة سوقية في عام 2022.

حسب البلد، يتم تقسيم سوق الصرع في منطقة آسيا والمحيط الهادئ إلى الصين واليابان والهند وأستراليا وكوريا الجنوبية وبقية منطقة آسيا والمحيط الهادئ. سيطرت الصين على حصة سوق الصرع في منطقة آسيا والمحيط الهادئ في عام 2022.

تعد Abbott Laboratories و Pfizer Inc و Eisai Co Ltd و UCB SA و LivaNova Plc و Novartis AG و Medtronic Plc و GSK Plc و H. Lundbeck AS من بين الشركات الرائدة العاملة في سوق الصرع في منطقة آسيا والمحيط الهادئ.

TABLE OF CONTENTS

 

1. Introduction

1.1 The Insight Partners Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

4.1 Pipeline Studies for Epilepsy Therapy Approaches

4.1.1 Cell and Gene Therapy Approaches

4.1.2 Encapsulated cell bio delivery (ECB) system

4.1.3 Gene Therapy for Epilepsy Clinical Overview

4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy

4.1.3.1.1 Gene Supplementation - Overview

4.1.3.1.2 Gene Modulation - Overview

4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview

4.1.3.1.4 Neuropeptides - Overview

4.1.3.1.5 Engineered Channels - Overview

4.1.3.1.6 Endogenous Channels - Overview

4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy

4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy

4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy

4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy

4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview

4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches

4.1.3.6 Potassium Channels For Human Epileptic Phenotypes

4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Epilepsy

5.1.2 Increasing Investments in Development of Epilepsy Therapies

5.2 Market Restraints

5.2.1 Recall of Products

5.3 Market Opportunities

5.3.1 Surge in Awareness Programs Conducted by Organizations

5.4 Future Trends

5.4.1 Gene Therapy as Promising Treatment Approach

5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

7.1 Overview

7.2 Progressive Myoclonic Epilepsy

7.2.1 Overview

7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.3 Reflex Epilepsy

7.3.1 Overview

7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.4 Generalized Epilepsy

7.4.1 Overview

7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

7.5 Other

7.5.1 Overview

7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

8.1 Overview

8.2 Oral

8.2.1 Overview

8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.3 Parenteral

8.3.1 Overview

8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

9.1 Overview

9.2 First Generation Drugs

9.2.1 Overview

9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.3 Second Generation Drugs

9.3.1 Overview

9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9.4 Third Generation Drugs

9.4.1 Overview

9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

10.1 Overview

10.2 Adult

10.2.1 Overview

10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10.3 Children

10.3.1 Overview

10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

11.1 Overview

11.2 Hospital Pharmacies

11.2.1 Overview

11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11.4 Others

11.4.1 Overview

11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

12.1 Asia Pacific Epilepsy Market Overview

12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)

12.1.1.1 China: Epilepsy Market Overview

12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.2.1 China: Epilepsy Market Breakdown, by Type

12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration

12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type

12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group

12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.3 Japan: Epilepsy Market Overview

12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type

12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration

12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type

12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group

12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.5 India: Epilepsy Market Overview

12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.6.1 India: Epilepsy Market Breakdown, by Type

12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration

12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type

12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group

12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.7 Australia: Epilepsy Market Overview

12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type

12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration

12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type

12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group

12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.9 South Korea: Epilepsy Market Overview

12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type

12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration

12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type

12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group

12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel

12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview

12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type

12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration

12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type

12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group

12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

13.1 Overview

13.2 Growth Strategies in Epilepsy Market

13.3 Organic Growth Strategies

13.3.1 Overview

13.4 Inorganic Growth Strategies

13.4.1 Overview

14. Company Profiles

14.1 Abbott Laboratories

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Eisai Co Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 UCB SA

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 LivaNova Plc

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Novartis AG

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 Medtronic Plc

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 GSK Plc

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 H. Lundbeck AS

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

15. Appendix

15.1 About The Insight Partners

?

List of Tables

Table 1. Asia Pacific Epilepsy Market Segmentation

Table 2. Cell Therapy Approach - An Overview

Table 3. Gene Therapy Approach - An Overview

Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview

Table 5. Preclinically Tested Genetic Therapies for Epilepsy

Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview

Table 7. Viral Vectors Comparison with respect to Various Parameters

Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies

Table 9. Enzyme-Inducing Antiepileptic Drugs

Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview

Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type

Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration

Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type

Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group

Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel

Table 41. Recent Organic Growth Strategies in Epilepsy Market

Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

?

List of Figures

Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country

Figure 2. Epilepsy Market - Key Market Dynamics

Figure 3. Impact Analysis of Drivers and Restraints

Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030

Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)

Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)

Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)

Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)

Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)

Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)

Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)

Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)

Figure 33. Growth Strategies in Epilepsy Market

 

  1. Abbott Laboratories
  2. Pfizer Inc
  3. Eisai Co Ltd
  4. UCB SA
  5. LivaNova Plc
  6. Novartis AG
  7. Medtronic Plc
  8. GSK Plc
  9. H. Lundbeck AS
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.
Report Code
Full Name
Country Name
Email Id
Phone Number
Job Title
Company
Requirement

Note : Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.


Purchase Options
Single User License
$3550
$2840
Site License
$4550
$3640
Enterprise License
$5550
$4440